ADAP Advocacy has released a retrospective white paper examining the 340B Drug Pricing Program, arguing that reform is necessary to realign the program with its original legislative intent of serving low-income and uninsured patients. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," outlines how the program has grown into the second-largest federal prescription drug program in the United States, behind Medicare Part D, but has veered off course by prioritizing provider interests over patient interests.
The white paper raises three central questions: If 340B is designed to expand access and reduce financial burden, why are patients increasingly unable to afford care? Why is 340B not adequately addressing this problem? And why is it failing to meet the needs of the uninsured and underinsured, the very persons it was designed to serve? These questions underscore the need for greater transparency across the healthcare system, including hospital billing practices and pharmacy benefit manager spread pricing policies.
Brandon M. Macsata, CEO of ADAP Advocacy, emphasized that the 340B Program should not be excluded from broader efforts to push for transparency. "The ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients," he stated.
The paper notes that what started as a support mechanism has grown into a massive financial integration within the healthcare system. It argues that a program of this size and importance cannot be entrusted to good faith alone; rather, improved accountability and transparency guardrails are needed to ensure its success for its intended beneficiaries: patients.
The full white paper is available on the ADAP Advocacy website at https://www.adapadvocacy.org/policycenter/340b. ADAP Advocacy works to promote and enhance AIDS Drug Assistance Programs and improve access to care for persons living with HIV/AIDS, collaborating with various stakeholders to raise awareness and foster community collaboration.
